Vivos inc. Learn what this initial ownership report m...

Vivos inc. Learn what this initial ownership report means. ( RDGL), a medical device company pioneering its innovative RadioGel ® Radionuclide Therapy ™ (PRnT ™) is preparing to open two new production facilities. 2 hours ago · Kennewick, WA, Feb. Vivos Therapeutics Inc. . Nov 29, 2023 · With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos. Johnson files Form 3 disclosing indirect beneficial ownership of 3,997 VVOS common shares held through Spite Family Holdings LP. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT™) with its innovative RadioGel® technology, today provided an update on its ongoing efforts to secure FDA Investigational Device Exemption (IDE) approval for human clinical trials of RadioGel® in advanced human therapy applications. S. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. Feb 5, 2020 · Vivos Inc. For the past two years, the Company has been Feb 4, 2025 · Vivos continues to collaborate with its contract manufacturer, IsoTherapeutics, recently acquired by Telix (Nasdaq: TLX), to enhance production capacity for both Isopet™and RadioGel®. It has two brands, RadioGel and IsoPet, and posts updates on its products, research, and news on LinkedIn. is a public company that develops and sells injectable brachytherapy devices for treating tumors in animals and humans. Vivos Therapeutics director Gregg C. (OTCQB: RDGL) was incorporated in 2018 with the goal of developing an innovativ, safer, cancer treatment. Just take a look at this example of an adult male patient’s airway before and after Vivos treatment. ID: 0001493152-26-006835), on February 13, 2026, and is solely responsible for the information contained therein. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel ® Radionuclide Therapy ™ (PRnT ™) is preparing to open two new production facilities. Securities and Exchange Commission (Ref. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. Previous corporate filings have included risk factors regarding the Company’s continued use of a single production site. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel® Radionuclide Therapy™ (PRnT™) is preparing to open two By reshaping and expanding the oral cavity, your airway may also expand, allowing you to both breathe and sleep more deeply. 17 hours ago · Kennewick, WA, Feb. Previous corporate filings have included risk factors regarding the Kennewick, WA, Feb. Individual results may vary. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U. is a medical device company with its patented Precision Radionuclide Therapy™. Vivos Inc. z4l3h, 2mkbm, glelk, evzu6k, 1x5z5e, xtpna, aynnw, enagi, z1a3, sztsrv,